Daniel Bradbury Net Worth

The estimated Net Worth of Daniel Bradbury is at least $160 Million dollars as of 5 September 2024. Mr. Bradbury owns over 7,867 units of Equillium Inc stock worth over $6,124 and over the last 21 years he sold EQ stock worth over $159,180,253. In addition, he makes $1,203,360 as Executive Chairman of the Board at Equillium Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Bradbury EQ stock SEC Form 4 insiders trading

Daniel has made over 153 trades of the Equillium Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he sold 7,867 units of EQ stock worth $228,300 on 5 September 2024.

The largest trade he's ever made was buying 179,000 units of Equillium Inc stock on 21 November 2012 worth over $248,810. On average, Daniel trades about 7,573 units every 26 days since 2004. As of 5 September 2024 he still owns at least 7,125 units of Equillium Inc stock.

You can see the complete history of Mr. Bradbury stock trades at the bottom of the page.

Daniel Bradbury biography

Daniel Mark Bradbury serves as Executive Chairman of the Board of the Company. He served as our Chief Executive Officer from June 2018 through December 2019. Mr. Bradbury is a co-founder of Equillium and served as our President from March 2017 until June 2018. Mr. Bradbury is the founder and has served as the managing member of BioBrit, LLC (“BioBrit”), a life science consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc., a publicly-held biopharmaceutical company, from March 2007 until Amylin’s acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr. Bradbury worked in marketing and sales for 10 years at SmithKline Beecham Pharmaceuticals, a privately-held pharmaceutical company. Mr. Bradbury serves on the board of directors of numerous private companies and the following publicly-held companies: Castle Biosciences, and Intercept Pharmaceuticals, Inc. Mr. Bradbury previously served on the board of directors of BioMed Realty Trust, Inc., a publicly-held real estate investment trust company, from 2013 to 2016; Corcept Therapeutics Incorporated, a publicly-held biotechnology company, from 2012 to 2019; Geron Corporation, a publicly-held biotechnology company, from 2012 to 2019; Illumina, Inc., a publicly-held biotechnology company, from 2004 to 2017; and Syngene International Ltd., a publicly-held science research company, from 2015 to 2016. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

What is the salary of Daniel Bradbury?

As the Executive Chairman of the Board of Equillium Inc, the total compensation of Daniel Bradbury at Equillium Inc is $1,203,360. There are 2 executives at Equillium Inc getting paid more, with Krishna Polu having the highest compensation of $1,508,120.

How old is Daniel Bradbury?

Daniel Bradbury is 59, he's been the Executive Chairman of the Board of Equillium Inc since 2020. There are 3 older and 14 younger executives at Equillium Inc. The oldest executive at Equillium Inc is Bala Manian, 74, who is the Independent Director.

What's Daniel Bradbury's mailing address?

Daniel's mailing address filed with the SEC is C/O CASTLE BIOSCIENCES, INC., 505 S. FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD, TX, 77546.

Insiders trading at Equillium Inc

Over the last 6 years, insiders at Equillium Inc have traded over $2,616,040 worth of Equillium Inc stock. The most active insiders traders include Daniel Bradbury, Mark Pruzanski, and Stephen Connelly. On average, Equillium Inc executives and independent directors trade stock every 95 days with the average trade being worth of $20,757. The most recent stock trade was executed by Jason A Keyes on 16 July 2024, trading 10,000 units of EQ stock currently worth $8,700.

What does Equillium Inc do?

equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.

Complete history of Mr. Bradbury stock trades at Corcept Therapeutics Inc, Geron, Illumina Inc, Intercept Pharmaceuticals Inc, Equillium Inc, and Castle Biosciences

Equillium Inc executives and stock owners

Equillium Inc executives and other stock owners filed with the SEC include:

• Krishna Polu,
  Executive Vice President - Research and Development, Chief Medical Officer
• Bruce Steel,
  President, Chief Executive Officer, Director
• Daniel Bradbury,
  Executive Chairman of the Board
• Dr. Krishna R. Polu,
  Consultant
• Dr. Stephen Connelly Ph.D.,
  Chief Scientific Officer & Director
• Bruce D. Steel C.F.A.,
  Co-Founder, Pres, CEO & Director
• Stephen Connelly,
  Chief Scientific Officer, Director
• Daniel Mark Bradbury,
  Exec. Chairman
• Mark Pruzanski,
  Independent Director
• Charles McDermott,
  Independent Director
• Bala Manian,
  Independent Director
• Martha Demski,
  Independent Director
• Matthew Ritter,
  Vice President - Corporate Development
• Maple Fung,
  Vice President - Clinical Development
• Christine Zedelmayer,
  Chief Operating Officer, Senior Vice President
• Jason Keyes,
  Chief Financial Officer
• Jason A. Keyes,
  Chief Financial Officer
• Dr. Dolca Thomas M.D.,
  Exec. VP of R&D and Chief Medical Officer
• Joel M. Rothman,
  Chief Devel. Officer
• Michael Moore,
  VP of Investor Relations & Corp. Communications
• Christine Zedelmayer M.B.A., P.M.P.,
  Sr. VP & COO
• Yu (Katherine) Xu,
  
• Sa Biocon,
  10% owner
• Dolca Thomas,
  Chief Medical Officer
• Joel Rothman,
  Chief Development Officer
• Barbara Troupin,